Article
Pharmacogenetic interactions of three candidate gene polymorphisms with ACE-inhibitors or beta-blockers and the risk of atherosclerosis.
British journal of clinical pharmacology - 1 Jul 2007
Schelleman H, Klungel O H, Witteman J C M, Hofman A, van Duijn C M, de Boer A, Stricker B H Ch
Abstract excerpt
AIMS: To investigate whether the angiotensin-converting enzyme (ACE) insertion/deletion (I/D), angiotensinogen M235T or angiotensin II receptor type 1 573C/T polymorphism modify the risk of atherosclerosis associated with beta-blocker or ACE-inhibitor therapy. METHODS: Data were used from the Rotterdam Study, a population-based prospective cohort study in the Netherlands, which started in 1990 and included 7983...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
